# Chest Pain as a Symptom of Early-Onset Metastatic Prostate Cancer: Exploring the Role of Screening

**Authors:** Fizza Mohsin, Brent Boodhai, Aarti Maharaj, Nissim Levy, Muhammad Hashim Khan, Fatima Sajid, Shaurya Sharma

PMC · DOI: 10.7759/cureus.78143 · 2025-01-28

## TL;DR

A 35-year-old man with chest pain was diagnosed with early-onset metastatic prostate cancer, highlighting the need for personalized screening in high-risk individuals.

## Contribution

This case emphasizes the importance of considering prostate cancer in young patients with atypical symptoms and a family history of the disease.

## Key findings

- A young patient with chest pain was found to have metastatic prostate cancer with rib lesions.
- Genetic testing revealed a BRCA2 mutation, indicating a more aggressive cancer type.
- The case underscores the need for tailored screening approaches in high-risk populations.

## Abstract

Prostate cancer is one of the most prevalent malignancies affecting males, primarily occurring in older men. However, it has been observed that there is a growing trend of new cases among younger individuals. We present the case of a 35-year-old male who had experienced persistent, severe right-sided chest pain for three months, unrelieved by analgesics. An inpatient workup revealed elevated alkaline phosphatase, prompting a more thorough evaluation that included measuring prostate-specific antigen (PSA) levels. His CT scan revealed sclerotic lesions in the ribs concerning metastatic disease. A biopsy of the enlarged retroperitoneal lymph nodes confirmed the diagnosis of metastatic prostate adenocarcinoma. Due to the patient's age and strong family history, genetic testing was conducted, revealing a BRCA2 mutation. Chest pain in a young patient can be misleading, and his symptoms did not initially suggest prostate cancer as a primary differential diagnosis. However, the persistence of symptoms, imaging results, and a strong family history of prostate cancer directed the physicians toward the correct diagnosis. Additionally, BRCA2 mutations are linked to a more aggressive form of the disease, and a timely diagnosis can lead to better outcomes. However, there is limited data regarding routine screening in high-risk patients such as African Americans and those with genetic predisposition. Therefore, healthcare providers should collaborate with their patients to develop personalized screening plans.

## Linked entities

- **Genes:** BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675]
- **Diseases:** prostate cancer (MONDO:0005159)

## Full-text entities

- **Genes:** BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675] {aka BRCC2, BROVCA2, FACD, FAD, FAD1, FANCD}, KLK3 (kallikrein related peptidase 3) [NCBI Gene 354] {aka APS, KLK2A1, PSA, hK3}
- **Diseases:** prostate adenocarcinoma (MESH:D000230), Chest Pain (MESH:D002637), malignancies (MESH:D009369), Prostate Cancer (MESH:D011471)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11867768/full.md

---
Source: https://tomesphere.com/paper/PMC11867768